Vincristine‐induced Eccrine Squamous Syringometaplasia

Thomas, Lacey M.; Mohr, Melinda R.; Smith, Michael L.; Boyd, Alan S.

doi:10.1111/j.1525-1470.2008.00809.x

Cited by 10 publications

(16 citation statements)

References 17 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eccrine squamous syringometaplasia has been well recognized as a cutaneous adverse drug reaction and chemotherapeutic agents, including doxorubicin, are most commonly reported as the cause 2,3 . The eruption has also been reported to occur in the vicinity of chronic ulcers, burns, panniculitis, pyoderma gangrenosum and linear scleroderma 1,8–10 .…”

Section: Discussionmentioning

confidence: 99%

“…Eccrine squamous syringometaplasia represents a distinctive cutaneous eruption that presents clinically as papules and plaques and that is characterized histopathologically by squamous metaplasia of eccrine ductal epithelium 1–3 . The condition has varied etiologies and can occur as a drug reaction, with chemotherapeutic drugs being frequently implicated 2,3 . Tamoxifen, an antiestrogenic agent, has been widely used as adjuvant hormonal therapy in the treatment of breast cancer.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tamoxifen‐induced eccrine squamous syringometaplasia

Teoh

Jaffar

et al. 2012

J Cutan Pathol

View full text Add to dashboard Cite

A 74-year-old woman had carcinoma of her right breast for which surgery was performed. Four weeks following the start of tamoxifen therapy, she developed papules and plaques over her face, trunk and limbs. A skin biopsy showed perivascular and periadnexal mixed inflammatory cellular infiltrate with fibroplasia. Notably, the dermis also showed squamous epithelial islands, which in foci were noted to be closely associated with eccrine epithelium. This was confirmed with double peroxidase - alkaline phosphatase immunohistochemistry - the eccrine lumina highlighted with carcinoembryonic antigen (polyclonal) and the squamous metaplasia positive for cytokeratin 5/6. Eccrine squamous syringometaplasia was diagnosed. With close clinicopathological correlation, the cutaneous eruption was attributed to tamoxifen. Following discontinuation of the drug, the eruption resolved. Eccrine squamous syringometaplasia has been reported to occur in association with diverse conditions, including skin ulcers, burns and as a cutaneous adverse drug reaction, most commonly to chemotherapeutic drugs. This is believed to be the first report involving tamoxifen.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Tamoxifen‐induced eccrine squamous syringometaplasia

Teoh

Jaffar

et al. 2012

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…17 Histopathologically, squamous metaplasia of eccrine ducts in the papillary dermis and the acrosiringia are the characteristic features. 14 To our knowledge, only 3 cases of ESS in association with nonchemotherapeutic agents have been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Most recently it has been documented after administration of sunitinib 16 and imatinib. 17 The pathogenesis of ESS remains unclear. Dauden et al 18 suggested that it represents a nonspecific reaction to damaged eccrine ductal epithelium induced by different stimuli, whereas Metcalf and Maize 19 proposed that inflammation induced ductal necrosis, in turn triggering squamous metaplasia.…”

Section: Discussionmentioning

confidence: 99%

Olanzapine-Induced Eccrine Squamous Syringometaplasia

Molina-Ruiz

Zulueta

et al. 2012

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Eccrine squamous syringometaplasia is a histopathologic pattern that has mainly been described in patients receiving chemotherapy. Its association to nonchemotherapeutic agents is rare, with very few cases reported in the literature. We present the case of a 55-year-old patient with schizophrenia, who developed a skin eruption 5 weeks after initiating treatment with olanzapine. The histopathologic study revealed squamous syringometaplasia of the dermal eccrine ducts.

show abstract

“…Although chemotherapy‐induced ESS is well described and associated with several agents, its underlying pathogenesis is not fully understood . Agents associated with ESS include busulfan, carmustine, cytarabine, cyclophosphamide, daunorubicin, doxorubicin, etoposide, cisplatin, 5‐fluorouracil, imatinib, methotrexate, melphalan, mitoxantrone, suramin, thiotepa, vemurafenib, and vincristine . Several authors have proposed that it is the result of damage to the eccrine ducts from high concentrations of chemotherapeutic agents in sweat .…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy‐induced eccrine squamous syringometaplasia in an infant

Bittar

Casady

Selim

et al. 2017

Pediatric Dermatology

View full text Add to dashboard Cite

There are few reports of chemotherapy-induced eccrine squamous syringometaplasia in children. We report the first case of an infant developing this condition after treatment with busulfan, fludarabine, and antithymocyte globulin in preparation for bone marrow transplantation. Twenty-eight days after transplantation, the infant developed faintly erythematous papules and plaques on the bilateral axillae, inguinal folds, and sites of adhesives. Punch biopsy revealed eccrine glands with dyskeratotic cells and focal squamous metaplasia consistent with chemotherapy-induced eccrine squamous syringometaplasia. | INTRODUCTIONEccrine squamous syringometaplasia (ESS) is defined as metaplasia of eccrine sweat ducts with transformation of the cuboidal epithelium of eccrine glands into two or more squamous layers.1 Two types of ESS have been described, chemotherapy-induced and incidental, that can be associated with several disorders. 2 When secondary to chemotherapy, the eruption is characterized by erythematous macules, papules, plaques, or vesicles in a generalized distribution or limited to the extremities, particularly the intertriginous and acral areas. 1-4 It typically appears 2-39 days after initiation of chemotherapy and has been associated with many agents. 2,3Despite the many identified causative agents, there are few reports of chemotherapy-induced ESS in children, with only two such cases in the literature. 3,4 We report a case of chemotherapyinduced ESS in a 7-month-old boy. To our knowledge, this is the first case of ESS reported in an infant. | CASE REPORTA 7-month-old boy with a history of Hurler's syndrome was admit-

show abstract

Vincristine‐induced Eccrine Squamous Syringometaplasia

Cited by 10 publications

References 17 publications

Tamoxifen‐induced eccrine squamous syringometaplasia

Tamoxifen‐induced eccrine squamous syringometaplasia

Olanzapine-Induced Eccrine Squamous Syringometaplasia

Chemotherapy‐induced eccrine squamous syringometaplasia in an infant

Contact Info

Product

Resources

About